PRINOXODAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H14N4O2
Molecular Weight	258.2759
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CC2=CC(=CC=C2NC1=O)C3=NNC(=O)CC3

InChI

InChIKey=SUCNEHPNQBBVHQ-UHFFFAOYSA-N

InChI=1S/C13H14N4O2/c1-17-7-9-6-8(2-3-10(9)14-13(17)19)11-4-5-12(18)16-15-11/h2-3,6H,4-5,7H2,1H3,(H,14,19)(H,16,18)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3243895 | https://www.ncbi.nlm.nih.gov/pubmed/1706794 | https://www.ncbi.nlm.nih.gov/pubmed/8494322

Prinoxodan (also known as RGW2938) is a benzodiazinone derivative patented by Rorer International (Overseas), Inc as inotropic agents, useful in treating congestive heart failure. Prinoxodan administered intravenously (i.v.) to anesthetized dogs increased contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. A single oral dose of Prinoxodan administered to conscious chronically instrumented dogs produced a marked and sustained increase in contractility 15-240 min after treatment.

Originator

Approval Year

PubMed

Title	Date	PubMed
Determination of a new inotropic agent in human plasma by high-performance liquid chromatography.	1988 Dec 28	3243895

Patents

Sample Use Guides

In Vivo Use Guide

Dog 0.3 mg/kg

Route of Administration: Oral

Name

Type

Language

PRINOXODAN

Official Name

English

PRINOXODAN [USAN]

Common Name

English

3,4-Dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2(1H)-quinazolinone

Systematic Name

English

RGW-2938

Code

English

prinoxodan [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744